Mapping the Knowledge Landscape of Antidiabetic Agent Research: A Scientometric Analysis of Trends, Collaboration, and Emerging Themes (2020–2026)

Anam Khan; Saiyed Faheem Ali; Bharti L Vaja; Rishika Singh; Shahnawaz Khan

doi:10.36948/ijfmr.2026.v08i05.88761

Mapping the Knowledge Landscape of Antidiabetic Agent Research: A Scientometric Analysis of Trends, Collaboration, and Emerging Themes (2020–2026)

Author(s)	Ms. Anam Khan, Prof. Dr. Saiyed Faheem Ali, Prof. Dr. Bharti L Vaja, Ms. Rishika Singh, Prof. Dr. Shahnawaz Khan
Country	India
Abstract	This study estimates the advancement of antidiabetic-agent research in the Journal of Medicinal Chemistry (JMC) during 2020–2026 concluded a scientometric valuation of 87 Scopus-indexed records. The collection comprises 72 research articles, 14 review papers and 0 errata, with a increasing citation count of 2,611. The publications received an average of 30.01 citations each, with a median of 13 citations and a calculated h-index of 26. Publication productivity reached its highest level in 2021, with 18 records, while 7 records were present in the 2026 snapshot. A strong collaborative pattern is manifest: 87 of the 87 records with recognizable author strings are multi-authored, giving a K. Subramanyam degree of collaboration of 1.00. The dataset contains 851 separate author-name strings and 978 Scopus author identifiers. Country analysis based on affiliation strings shows Italy, the United States, China, India, Germany and France among the most frequently represented national affiliations. Scopus Index Keywords emphasize antidiabetic agents, diabetes mellitus, insulin, protein-tyrosine phosphatase 1B, glucose transport, glucagon-like peptide-1, α-glucosidase, metabolic signaling and related therapeutic thoughts. The literature progressively combines small-molecule enzyme and transporter inhibition with peptide engineering, metabolic inflammation incretin pharmacology, β-cell biology and translational drug discovery. Highly cited records include studies of oral GLP-1 receptor agonism, insulin, cagrilintide, DYRK1A, PTP1B inhibitors, NLRP3 and metabolic signaling. Overall, the results show a multidisciplinary and strongly collaborative JMC landscape in which predictable glucose-lowering approaches coexist with receptor-selective, pathway-directed and peptide-based approaches.
Keywords	bibliometrics; scientometrics; Journal of Medicinal Chemistry; antidiabetic agents; α-glucosidase; metabolic disease; medicinal chemistry; diabetes mellitus; GLP-1 receptor; insulin; PTP1B; SGLT; DYRK1A; drug discovery.
Field	Computer > Data / Information
Published In	Volume 8, Issue 5, September-October 2026
Published On	2026-09-30
DOI	https://doi.org/10.36948/ijfmr.2026.v08i05.88761

View / Download PDF File

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Mapping the Knowledge Landscape of Antidiabetic Agent Research: A Scientometric Analysis of Trends, Collaboration, and Emerging Themes (2020–2026)

Share this